hsa-mir-652: Hsa-mir-652 is a microRNA that has been identified in various studies across different organisms, including humans and horses [PMC5424272]. It has been associated with different conditions and diseases, such as NOA (non-obstructive azoospermia) [PMC5226495], breast cancer [PMC5966243], metabolic syndrome [PMC3216936], schizophrenia [PMC3726785], pancreatic cancer [PMC7352720], PTCL/NOS (peripheral T-cell lymphoma, not otherwise specified) and ALCL/ALK- (anaplastic large cell lymphoma, anaplastic lymphoma kinase-negative) subtypes [PMC4335255]. Hsa-mir-652 has also been found to be dysregulated in alcoholics and is one of the highly expressed microRNAs in salivary microvesicles [PMC5858605] [PMC3422169]. It has been identified as a potential biomarker for early-stage breast cancer detection and for predicting the outcomes of patients with triple-negative breast cancer (TNBC) [PMC5966243] [PMC7499949]. Additionally, hsa-mir-652 has conserved mRNA targets such as ISL1, ACVR2B, and PSKH1 according to the Target Scan database [PMC3216936]. Furthermore, hsa-mir-652 is one of the miRNAs that can predict gene expression regulation in prostate cancer (PCa) when combined with other miRNAs such as hsa-mir-187 and hsa-mir-450b[ PMC8426106]. Overall, hsa-mir-652 plays a role in various biological processes and may have potential diagnostic or prognostic value in different diseases.